Taysha Gene Therapies (NASDAQ:TSHA) Receives “Market Outperform” Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

A number of other equities research analysts have also weighed in on TSHA. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday. Canaccord Genuity Group dropped their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Finally, Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $6.38.

Taysha Gene Therapies Trading Up 46.6 %

NASDAQ TSHA opened at $2.39 on Tuesday. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The business has a 50 day moving average price of $1.97 and a 200-day moving average price of $2.39. The company has a market cap of $489.81 million, a price-to-earnings ratio of -10.40 and a beta of 0.44.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. During the same quarter in the previous year, the business posted ($0.38) EPS. As a group, equities analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Creative Planning purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter worth about $28,000. Principal Financial Group Inc. bought a new stake in Taysha Gene Therapies in the second quarter worth about $48,000. China Universal Asset Management Co. Ltd. boosted its stake in Taysha Gene Therapies by 79.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after acquiring an additional 17,446 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at approximately $85,000. Finally, Scientech Research LLC purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $97,000. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.